Aurinia Pharmaceuticals (AUPH) has released an update.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Aurinia Pharmaceuticals Inc. is set to participate in the 2024 Jefferies Global Healthcare Conference in New York, where it will engage in one-on-one investor meetings and give a presentation scheduled for June 5. The company will also provide a live webcast of the event accessible via their website. Aurinia is recognized for introducing LUPKYNIS, the first FDA-approved oral treatment for adult lupus nephritis patients, and operates globally with a focus on autoimmune diseases.
For further insights into AUPH stock, check out TipRanks’ Stock Analysis page.
